Request Demo

Last update 03 Apr 2026

Etavopivat

Last update 03 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1h)-yl)-3-hydroxy-2-phenylpropan-1-one, FT 4202, FT-4202

Target

PKLR

Action

agonists

Mechanism

PKLR agonists(Pyruvate kinase isozymes R/L agonists)

Therapeutic Areas

Congenital DisordersHemic and Lymphatic DiseasesOther Diseases+ [3]

Active Indication

Anemia, Sickle CellThalassemiaMyelodysplastic Syndromes+ [3]

Inactive Indication-

Originator Organization

Forma Therapeutics Holdings, Inc.

Active Organization

Novo Nordisk A/S

Forma Therapeutics, Inc.

Inactive Organization-

License Organization

Novo Nordisk A/SForma Therapeutics Holdings, Inc.

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Fast Track (United States)

Structure/Sequence

Molecular FormulaC22H23N3O6S

InChIKeyKZFFYEPYCVDOGE-LJQANCHMSA-N

CAS Registry2245053-57-8

Clinical Trials associated with Etavopivat

PACTR202408476236496

/ SuspendedPhase 3

An open-label, multi-centre, rollover study to characterise long-term safety andefficacy of etavopivat in adults, adolescents and children who have sickle cell disease orthalassaemia and have completed a treatment period in an etavopivat study

Start Date31 Jul 2025

Sponsor / Collaborator-

NCT07023029

/ CompletedPhase 1

A Study to Assess the Effect of Etavopivat on Cardiac Repolarisation in Healthy Participants

Novo Nordisk is developing a new study medicine, Etavopivat, to treat individuals with sickle cell disease (SCD). The purpose of the study is to determine the effect of Etavopivat on the electrical activity of the heart in healthy participants. The study comprises two parts: Part A and Part B. Part A investigates the safety of a high dose of Etavopivat. In this phase, participants will receive either a single dose of Etavopivat or a placebo. Which treatment the participant gets is decided by chance. In Part B, participants will get four different treatments on four different occasions: Etavopivat in 2 different doses (the new medicine that cannot be prescribed), a dummy medicine (placebo), and an already approved medicine (moxifloxacin). The order of the 4 study medicines is decided by chance. There will be a break of 7 days between each treatment. For Part A, the study duration will be from 10 to 36 days, and for Part B, the study duration will be from 27 to 53 days.

Start Date09 Jun 2025

Sponsor / Collaborator

Novo Nordisk A/S

NCT06612268

/ RecruitingPhase 3

A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease

This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.

Start Date17 Feb 2025

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Etavopivat

100 Translational Medicine associated with Etavopivat

100 Patents (Medical) associated with Etavopivat

Literatures (Medical) associated with Etavopivat

01 Jan 2025·EXPERIMENTAL HEMATOLOGY

FT-4202, a selective pyruvate kinase R activator for sickle cell disease

Article

Author: Marcotte, Douglas ; Ericsson, Anna ; Kuypers, Frans A ; Larkin, Sandra ; Troccolo, Paul ; Richard, David J ; Fulzele, Keertik ; Yao, Lili ; Toms, Angela ; Zheng, Xiaozhang ; Wilker, Erik ; Guichard, Sylvie M ; Marshall, Gary ; Ribadeneira, Maria ; Fessler, Shawn ; Lancia, David R ; Dinsmore, Christopher

Anemia in patients with sickle cell disease (SCD) increases 2,3-diphosphoglycerate (2,3-DPG), decreasing hemoglobin-oxygen (HbO₂) affinity to improve oxygen offloading and promote hemoglobin polymerization (sickling) of red blood cells (RBCs). We report the discovery of FT-4202, an investigational, selective pyruvate kinase type-R (PKR) activator with a multimodal mechanism of action and potential to increase ATP and decrease 2,3-DPG, resulting in increased HbO₂ affinity, decreased Hb polymerization, and improved RBC health. FT-4202 was identified via structure-enabled lead optimization medicinal chemistry using X-ray crystallography, molecular modeling, and thermal shift assays. FT-4202, an allosteric PKR activator, stabilizes the tetrameric enzyme and increases PKR activity in human and mouse RBCs in vitro. Seven-day oral administration of FT-4202 in Berkeley SCD mice reduced 2,3-DPG, increased HbO₂ affinity, and reduced RBC sickling versus control. There were no adverse in vitro safety findings. FT-4202 offers a therapeutic opportunity to modify the course of SCD.

27 Aug 2024·Blood advances

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Article

Author: Sanjeev Forsyth ; Frans A. Kuypers ; Kimberly Cruz ; Theodosia A. Kalfa ; Robert Hagar ; Maria Ribadeneira ; Ifeyinwa Osunkwo ; James Geib ; Patrick F. Kelly ; Modupe Idowu ; Eric Wu ; Marilyn J. Telen ; Santosh L. Saraf ; R. Clark Brown ; Patricia Schroeder

Abstract:

Etavopivat is an investigational, once daily, oral, selective erythrocyte pyruvate kinase (PKR) activator. A multicenter, randomized, placebo-controlled, double-blind, 3-part, phase 1 study was conducted to characterize the safety and clinical activity of etavopivat. Thirty-six patients with sickle cell disease (SCD) were enrolled into 4 cohorts: 1 single-dose, 2 multiple ascending doses, and 1 open-label (OL). In the OL cohort, 15 patients (median age 33.0 years [range, 17-55]) received 400 mg etavopivat once daily for 12 weeks; 14 patients completed treatment. Consistent with the mechanism of PKR activation, increases in adenosine triphosphate and decreases in 2,3-diphosphoglycerate were observed and sustained over 12 weeks’ treatment. This translated clinically to an increase in hemoglobin (Hb; mean maximal increase 1.6 g/dL [range, 0.8-2.8]), with >1 g/dL increase in 11 (73%) patients during treatment. In addition, the oxygen tension at which Hb is 50% saturated was reduced (P = .0007) with a concomitant shift in point of sickling (P = .0034) to lower oxygen tension in oxygen-gradient ektacytometry. Hemolysis markers (absolute reticulocyte count, indirect bilirubin, and lactate dehydrogenase) decreased from baseline, along with matrix metalloproteinase-9 and erythropoietin. In the OL cohort, adverse events (AEs) were mostly grade 1/2, consistent with underlying SCD; 5 patients had serious AEs. Vaso-occlusive pain episode was the most common treatment-emergent AE (n = 7) in the OL cohort. In this, to our knowledge, the first study of etavopivat in SCD, 400 mg once daily for 12 weeks was well tolerated, resulting in rapid and sustained increases in Hb, improved red blood cell physiology, and decreased hemolysis. This trial was registered at www.ClinicalTrials.gov as #NCT03815695.

01 May 2024·Clinical pharmacology and therapeutics

Quantitative Model‐Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination

Article

Author: Moody, Amy T. ; Maurer, Tristan S. ; Narula, Jatin

Three sickle cell disease (SCD) treatment strategies, stabilizing oxygenated hemoglobin (oxyHb), lowering 2,3‐BPG, and inducing fetal hemoglobin (HbF) expression aim to prevent red blood cell (RBC) sickling by reducing tense‐state sickle hemoglobin that contributes to polymer formation. Induction of 30% HbF is seen as the gold standard because 30% endogenous expression is associated with a lack of symptoms. However, the level of intervention required to achieve equivalent polymerization protection by the other strategies is uncertain, and there is little understanding of how these approaches could work in combination. We sought to develop an oxygen saturation model that could assess polymerization protection of all three approaches alone or in combination by extending the Monod‐Wymann‐Changeux model to include additional mechanisms. Applying the model to monotherapies suggests 51% sickle hemoglobin (HbS) occupancy with an oxyHb stabilizer or lowering RBC 2,3 BPG concentrations to 1.8 mM would produce comparable polymerization protection as 30% HbF. The model predictions are consistent with observed clinical response to the oxyHb stabilizer voxelotor and the 2,3‐BPG reducer etavopivat. The model also suggests combination therapy will have added benefit in the case of dose limitations, as is the case for voxelotor, which the model predicts could be combined with 20% HbF or 2,3‐BPG reduction to 3.75 mM to reach equivalent protection as 30% HbF. The proposed model represents a unified framework that is useful in supporting decisions in preclinical and early clinical development and capable of evolving with clinical experience to gain new and increasingly confident insights into treatment strategies for SCD.

News (Medical) associated with Etavopivat

04 Feb 2026

·www.biospace.com

Novo Nordisk’s sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025

Bagsværd, Denmark 3 February 2026 - Financial report for the period 1 January 2025 to 31 December 2025 Operating profit decreased by 1% in Danish kroner and increased by 6% at constant exchange rates (CER) to DKK 127.7 billion. Had Novo Nordisk not incurred costs related to the company-wide transformation of around DKK 8 billion, operating profit would have increased by 6% in Danish kroner and 13% at CER. Sales in US Operations increased by 3% in Danish kroner (8% at CER) and were positively impacted by gross-to-net sales adjustments. Sales in International Operations increased by 10% in Danish kroner (14% at CER). Sales within Obesity and Diabetes care increased by 7% in Danish kroner to DKK 289.5 billion (10% at CER), mainly driven by Obesity care growth of 26% in Danish kroner (31% at CER) and GLP-1 diabetes sales growing 2% in Danish kroner (6% at CER). Rare disease sales increased by 5% in Danish kroner (9% at CER). On 22 December, the US FDA approved the first oral GLP-1 in obesity, once-daily oral semaglutide 25 mg, under the brand name of Wegovy ® pill. Wegovy ® pill was launched on 5 January 2026, and as of 23 January, total weekly prescriptions amounted to around 50,000. Prescription uptake is mainly driven by the 1.5 mg starter dose in the self-pay channel. Key R&D developments in the quarter include the phase 2 trial with zenagamtide (previously amycretin) showing significant weight loss and HbA 1c reduction in type 2 diabetes, and the phase 3 trial REIMAGINE 2 with CagriSema, also in diabetes, was successfully completed. Within obesity, Novo Nordisk has submitted semaglutide 7.2 mg and the next-generation asset CagriSema to the US FDA. Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, is expected to be -5 to -13% at CER. Adjusted sales growth reported in Danish kroner is expected to be 3 percentage points lower than at CER. The sales outlook is impacted by lower realised prices, including impacts related to the "Most Favoured Nations" agreement in the US and the patent expiry of the semaglutide molecule in certain IO markets, as well as competition. The global GLP-1 market is expected to continue to expand with Novo Nordisk introducing new treatments, such as Wegovy ® pill and higher doses of Wegovy ® , enabling Novo Nordisk to continue to increase patient reach and expand volumes. Adjusted operating profit growth is expected to be -5 to -13% at CER. Adjusted operating profit growth reported in Danish kroner is expected to be 5 percentage points lower than at CER. Sales and operating profit for 2026 will be positively impacted by a reversal of sales rebate provisions of USD 4.2 billion related to the 340B Drug Pricing Program in the US. At the Annual General Meeting on 26 March 2026, the Board of Directors will propose a final dividend of DKK 7.95 per share for 2025, taking the expected total dividend for 2025 to 11.70. The Board of Directors has decided to initiate a new share repurchase programme of up to DKK 15 billion. PROFIT AND LOSS 2025 2024 Growth as reported Growth at CER* DKK million Net sales 309,064 290,403 6% 10% Operating profit 127,658 128,339 (1%) 6% Net profit 102,434 100,988 1% N/A Diluted earnings per share (in DKK) 23.03 22.63 2% N/A * CER: Constant exchange rates (average 2024). "Novo Nordisk delivered 10% sales growth in constant exchange rates and reached nearly 46 million people with our innovative treatments, despite 2025 being a challenging year for the company. In 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market. However, we are very encouraged by the promising early uptake from the US launch of Wegovy ® pill, and we remain confident in our ability to drive volume growth over the coming years. Also for this year, we look forward to regulatory decisions for next-generation treatments, such as Mim8 within haemophilia and CagriSema within obesity, as well as a number of exciting R&D read-outs, including phase 3 read-outs for etavopivat and ziltivekimab," said Mike Doustdar, president and CEO. On 3 February 2026 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K). A bout Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com Investors: Michael Novod +45 3075 6050 nvno@novonordisk.com Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com Max Ung +45 3077 6414 mxun@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com Alex Bruce +45 3444 2613 axeu@novonordisk.com Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com Company announcement No 4 / 2026 Attachment CA260203-Q4-2025

Drug ApprovalPhase 3Phase 2Biosimilar

16 Oct 2025

·www.pharmaceutical-technology.com

Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn

Novo Nordisk has agreed to acquire the development and commercialisation rights to Omeros’ former lead rare blood disease asset, zaltenibart, in a deal worth up to $2.1bn. Image credit: Kittyfly via ShutterStock.com. Danish pharma giant Novo Nordisk has inked a definitive deal with Omeros Corporation to acquire its late-stage-ready rare disease asset, zaltenibart. By selling the rights to the monoclonal antibody (mAb), which demonstrated potential in a Phase II trial in blood disorder paroxysmal nocturnal haemoglobinuria (PNH), Omeros will pocket $340m in upfront and short-term milestone payments. The biotech is also eligible to receive up to $2.1bn in development and commercial milestone payments from Novo Nordisk, depending on how the drug performs in upcoming Phase III trials in PNH. These studies will be initiated and funded by Novo Nordisk. Formerly known as OMS906, zaltenibart was due to enter Phase III clinical trials under Omeros’ name , but the company later pressed pause on the drug’s late-stage development. This came after Omeros forecasted a “ramp up in spending” on these studies, which led the biopharma to “prioritise” the use of capital currently available to it. Zaltenibart’s financial performance could bode well for the rest of Omeros’ pipeline, according to investor reaction. The company’s stock value shot up more than 180% after the news debuted, going from $4.10 at market close on 14 October to $11.59 at market open on 15 October. Novo’s choice to purchase zaltenibart will bolster the company’s rare blood disease pipeline, which currently includes five drugs in Phases I to III. This includes erythrocyte pyruvate kinase (PKR) activator etavopivat, which the pharma obtained through its acquisition of Forma in 2022 and is now in Phase III trials for sickle cell disease. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Zaltenibart’s future potential Zaltenibart works by inhibiting the mannan-binding lectin-associated serine protease-3 (MASP-3), a complement system enzyme that is key to activating the alternative pathway. According to Sir Peter Lachmann , Emeritus Sheila Joan Smith Professor of Immunology at the University of Cambridge, MASP-3 inhibitors such as zaltenibart could have “important advantages relative to a complement 5 (C5) inhibitor,” for treating PNH. Lachmann noted that this was likely due to zaltenibart’s ability to block both intra- and extravascular haemolysis, which he said C5 inhibitors cannot achieve. As a result, zaltenibart could take a chunk of the PNH market if approved. The indication is currently dominated by C5 inhibitors such as AstraZeneca’s Soliris (eculizumab) and Ultomiris (ravulizumab). However, the recent market debut of Novartis’ Fabhalta (iptacopan) could be a spanner in the works for intravenous (IV) therapies like zaltenibart, as the drug is orally administered – enhancing patient convenience. Outside of PNH, Omeros has previously touted the potential of the mAb in other rare blood and kidney disorders. Following its acquisition of zaltenibart, Novo Nordisk will explore further development opportunities for the drug in a “range” of undisclosed indications. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

AcquisitionPhase 2Phase 3Drug Approval

04 Sep 2025

·endpoints.news

FDA delays decision on Agios drug in thalassemia over liver safety

The FDA pushed back its decision date by three months for Agios Pharmaceuticals’ drug Pyrukynd in thalassemia, the Cambridge, MA-based company announced Thursday morning. The agency’s decision was expected by Sept. 7, but that deadline has now been moved to Dec. 7. Agios said it submitted a proposal for a drug safety monitoring program called REMS to reduce the risk of liver injury with Pyrukynd, resulting in the three-month delay. Last year, Agios reported that two of 301 patients who received the drug in a trial for transfusion-dependent thalassemia had liver damage in the first six months on the therapy, which led them to stop treatment. Agios’ shares $AGIO fell 17% Thursday premarket. Thalassemia is a genetic blood disorder that interferes with a person’s ability to make healthy red blood cells. Some patients require regular blood transfusions to live, while others don’t — though those patients may need transfusions at times. The biotech is seeking approval of Pyrukynd in all adult patients with thalassemia after studying the drug in transfusion-dependent and transfusion-independent patients with either alpha or beta thalassemia. An approval would mark a key expansion for the drug, which is also known as mitapivat. It was previously approved to treat a rare condition called pyruvate kinase deficiency. In August, Pyrukynd was cleared by Saudi Arabia for thalassemia, its first approval in the disease. The company is also expecting results from a Phase 3 sickle cell study later this year. In the second quarter, Agios reported that Pyrukynd generated $12.5 million in sales. Wall Street analysts believe that the drug can become a multibillion-dollar product after adding thalassemia and sickle cell indications. Agios’ key competitor is Novo Nordisk, which acquired a similar drug called etavopivat through its $1.1 billion purchase of Forma Therapeutics in 2022. Novo is also studying etavopivat in late-stage trials with sickle cell disease and thalassemia patients.

Drug ApprovalPhase 3Clinical Result

100 Deals associated with Etavopivat

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia, Sickle Cell	Phase 3	United States	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	Canada	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	Egypt	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	France	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	Germany	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	Ghana	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	Greece	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	India	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	Italy	Novo Nordisk A/S	10 Jan 2025
Anemia, Sickle Cell	Phase 3	Kenya	Novo Nordisk A/S	10 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06612268 (HIBISCUS 2, ASH2025)	Phase 3	Anemia, Sickle Cell	408	Etavopivat 400 mg	ssmxzvueco(kuqiefeuqh) = gvdimifmbc jxmcnzxewk (ixitwlrged )	Positive	06 Dec 2025
NCT06612268 (HIBISCUS 2, ASH2025)	Phase 3	Anemia, Sickle Cell	408	Placebo	ssmxzvueco(kuqiefeuqh) = rampiplbur jxmcnzxewk (ixitwlrged ) View more	Positive	06 Dec 2025
NCT06198712 (HIBISCUS Kids, ASH2025)	Phase 1/2	Anemia, Sickle Cell	15	Etavopivat 400 mg	wrnwbgaonf(hcewordpqq) = One participant required a dose interruption due to a drug-related SAE (cholestasis), which resolved. vkwpbwukzh (xkgeqxprwb ) View more	Positive	06 Dec 2025
NCT05568225 (CTgov)	Phase 2	Anemia \| Myelodysplastic Syndromes	17	etavopivat (Non-transfusion Dependent)	syzjectqhs = xcykdusbpw idiorwfkbv (nivrpcupcc, pkbngahiwe - vvofsjvqhl) View more	-	22 Oct 2025
NCT05568225 (CTgov)	Phase 2	Anemia \| Myelodysplastic Syndromes	17	etavopivat (Low Transfusion Burden)	syzjectqhs = hzavkdmpuv idiorwfkbv (nivrpcupcc, dvjxjeotkc - bmxsboqyeu) View more	-	22 Oct 2025
NCT04624659 (HIBISCUS, ASH2024) Manual	Phase 2/3	Anemia, Sickle Cell	60	Etavopivat 200 mg	vhisddpsev(sbjuwbyevw) = qnrtbwxlej hcxynwtdpc (tlqmvpdipx ) View more	Positive	07 Dec 2024
NCT04624659 (HIBISCUS, ASH2024) Manual	Phase 2/3	Anemia, Sickle Cell	60	Etavopivat 400 mg	vhisddpsev(sbjuwbyevw) = gboksktnui hcxynwtdpc (tlqmvpdipx ) View more	Positive	07 Dec 2024
NCT03815695 (Pubmed \| Blood Adv) Manual	Phase 1	Anemia, Sickle Cell adenosine triphosphate \| 2,3-diphosphoglycerate \| hemoglobin ... View more	-	Etavopivat 400 mg	zsrfhoeyyt(bdmwxenrby) = Adverse events (AEs) were mostly grade 1/2, consistent with underlying SCD. mlpjttgphh (bpqdnkvlzr )	Positive	27 Aug 2024
NCT03815695 (EHA2022) Manual	Phase 1	Anemia, Sickle Cell	15	etavopivat 400 mg	tgsdmtwtht(cqxjjkrlob) = On-tx serious adverse events (SAEs; 1 pt each) were Gr3 VOC post Gr3 COVID (not tx-related) and Gr3 left femoral deep vein thrombosis (possibly related, resulting in tx discontinuation as stated above) upmmjcfwbx (nsixjuuuns ) View more	Positive	12 May 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Etavopivat

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation